Journal article · 2026 · Open access
Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs
Clinical Pharmacology & Therapeutics · Published 29 October 2026 · DOI 10.1002/cpt.70535
In brief
“Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs” is a 2026 journal article by Johannes Tillil and 6 co-authors, published in Clinical Pharmacology & Therapeutics. OpenAlex counts 0 citations as of 17 November 2026. It is open access under a CC BY-NC licence: the full text is free to read at Clinical Pharmacology & Therapeutics.
- Citations
- 0
- References
- 22
- Authors
- 7
Abstract
Chronic inflammation has long been known to downregulate the activity of certain cytochrome P450 (CYP) enzymes-the main enzymes responsible for the phase I metabolism of many small molecule drugs-potentially leading to higher exposures in patients with chronic inflammatory diseases compared to healthy volunteers. Neglecting this potential difference in the pharmacokinetics can have several implications for dose translation from healthy volunteers to proof of concept studies in patients: sub-optimal design of dose-ranging studies and increased risk of adverse events due to overprediction of safety margins. Yet this disease-drug interaction has rarely been prospectively considered in drug development in the past. This review aims to quantify the extent of decreased (apparent) clearance in patients compared to healthy volunteers of small molecule drugs that were approved by the FDA in the past 15 years for important chronic inflammatory indications. Based on reported population pharmacokinetic analyses, 25% (5 of 20) of small molecule drugs approved for the selected indications showed a meaningfully higher area under the curve (AUC) by more than 25% in patients compared to healthy volunteers. As a common feature, all five drugs are primarily metabolized by CYP3A4 or CYP2C19 and for four of the five drugs, the contribution of metabolism to their elimination is more than 50%. These findings highlight the need to assess a drug's susceptibility to changes in the metabolic activity under chronic inflammation when translating dose predictions from healthy volunteers to patients.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Tillil, J., Gopalakrishnan, S., Dong, J. Q., Venkatakrishnan, K., Kloft, C., Huisinga, W., & Klopp‐Schulze, L. (2026). Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70535
MLA 9
Tillil, Johannes, et al. “Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs.” Clinical Pharmacology & Therapeutics, 2026. https://doi.org/10.1002/cpt.70535.
Chicago
Tillil, Johannes, Sathej Gopalakrishnan, Jennifer Q. Dong, Karthik Venkatakrishnan, Charlotte Kloft, Wilhelm Huisinga, and Lena Klopp‐Schulze. 2026. “Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs.” Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70535.
Harvard
Tillil, J. et al. (2026) ‘Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs’, Clinical Pharmacology & Therapeutics. doi:10.1002/cpt.70535.
IEEE
J. Tillil et al., “Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs,” Clinical Pharmacology & Therapeutics, 2026, doi: 10.1002/cpt.70535.
BibTeX
@article{tillil2026patients,
title = {{Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs}},
author = {Tillil, Johannes and Gopalakrishnan, Sathej and Dong, Jennifer Q. and Venkatakrishnan, Karthik and Kloft, Charlotte and Huisinga, Wilhelm and Klopp‐Schulze, Lena},
journal = {Clinical Pharmacology \& Therapeutics},
year = {2026},
doi = {10.1002/cpt.70535},
url = {https://doi.org/10.1002/cpt.70535}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- chronic inflammatory diseases
- drug exposure
- cytochrome P450 inhibition
- CYP3A4
- CYP2C19
- small molecule drugs
- drug metabolism
- population pharmacokinetics
Work with this paper
Most-cited papers in Pharmacology, Toxicology and Pharmaceutics
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingOleg Trott, Arthur J. Olson · Journal of Computational Chemistry · 2009 · 39,860 citations
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityGarrett M. Morris, Ruth Huey, William Lindstrom and 4 more · Journal of Computational Chemistry · 2009 · 26,508 citations
- Development and testing of a general amber force fieldJunmei Wang, Romain M. Wolf, James W. Caldwell and 2 more · Journal of Computational Chemistry · 2004 · 20,080 citations
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Christopher A. Lipinski, Franco Lombardo, Beryl W. Dominy and 1 more · Advanced Drug Delivery Reviews · 2001 · 19,638 citations
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small moleculesAntoine Daina, Olivier Alain Michielin, Vincent Zoete · Scientific Reports · 2017 · 19,557 citations
All highly cited Pharmacology, Toxicology and Pharmaceutics papers
Questions about this paper
How do I cite this paper in APA style?
Tillil, J., Gopalakrishnan, S., Dong, J. Q., Venkatakrishnan, K., Kloft, C., Huisinga, W., & Klopp‐Schulze, L. (2026). Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70535
How many times has this paper been cited?
0 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Clinical Pharmacology & Therapeutics: sign in and open the PDF from this page.
Who wrote this paper?
Johannes Tillil, Sathej Gopalakrishnan, Jennifer Q. Dong, Karthik Venkatakrishnan, Charlotte Kloft, Wilhelm Huisinga, Lena Klopp‐Schulze.
What is the DOI of this paper?
10.1002/cpt.70535, permanently at https://doi.org/10.1002/cpt.70535. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.